Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASGCT 2021 | DARIC33 CAR T-cells in AML

Jacob Appelbaum, MD, PhD, University of Washington, Seattle, WA, describes pre-clinical research investigating dimerizing agent regulated immunoreceptor complex targeting CD33 (DARIC33) chimeric antigen receptor (CAR) T-cells for the treatment of acute myeloid leukemia (AML). This study demonstrated the ability to pharmacologically control the anti-CD33 activity of DARIC33 T cells through the pulsatile dosing of rapamycin, as well as the ability to modulate anti-tumor activity of DARIC33 T cells using rapamycin in a mouse model. The superior control that DARIC33 provides over CAR-T cells may facilitate the development of more broadly applicable and potent CAR T-cell therapies, using multiplex targeting technology and potency enhancement. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.